Register now for the 2nd Annual Conference on Precision Psychiatry: "Innovation to Implementation", hosted by the MGH Center for Precision Psychiatry in partnership with PNGU and the MGH Psychiatry Academy.
This year, our Keynote Speakers will be Dr. Kelsey Martin, Director of the Simons Foundation Autism Research Initiative (SFARI), and Dr. Thomas Insel, former Director of NIMH and author of Healing: Our Path from Mental Illness to Mental Health (Penguin Press, 2022).
The Conference is designed to cover a broad range of domains including: applications of AI & machine learning in psychiatry, genomics and other omics, precision therapeutics, risk stratification for suicide and other important outcomes, mHealth and digital technologies, implementation science, and ethics and equity.
For more information and to register for the Conference, visit https://mghcme.org/precision2022.
Save the date! The second annual Conference on Precision Psychiatry will be held on November 2nd and November 3rd, 2022 and will feature keynote speakers Kelsey Martin and Tom Insel. More details to come.
Individuals at high risk for schizophrenia may benefit from early intervention, but few validated risk predictors are available. Genetic profiling is one approach to risk stratification that has been extensively validated in research cohorts.
With information provided by volunteers across the United States, All of Us is developing a robust data platform to support a wide range of health studies.
Researchers have identified specific genes that may trigger the development of sleep problems, and have also demonstrated a genetic link between insomnia and psychiatric disorders such as depression, or physical conditions such as type 2 diabetes.
This summer, I got an email with the subject line, “Help researchers at Mass. General or the Brigham make discoveries.” Think the Boston hospitals — Massachusetts General Hospital and Brigham and Women's Hospital — were hitting me up for a check? Wrong.
Mental illness affects one in six U.S. adults, but scientists' sense of the underlying biology of most psychiatric disorders remains nebulous. That's frustrating for physicians treating the diseases, who must also make diagnoses based on symptoms that may only appear sporadically. No laboratory blood test or brain scan can yet distinguish whether someone has depression or bipolar disorder, for example.
Attention deficit hyperactivity disorder, major depression, bipolar disorder and schizophrenia may be linked by common genetic risk factors, according to a new study published in The Lancet. Audie Cornish speaks with study author Jordan Smoller of Harvard Medical School.
For the first time, researchers have identified two genetic variants that predispose humans to major depressive disorder, according to a study published in Nature today. The finding is specific to Han Chinese women, so this isn't a universally relevant piece of information. Still, this discovery could help researchers get a handle on the biology of depression — in addition to enabling the identification of new drug targets.
Massachusetts General Hospital
Simches Research Building
185 Cambridge Street
Boston, MA 02114